RNAC R&D to Revenue
Cartesian Therapeutics Inc · R&D to Revenue
RNAC R&D to Revenue
Latest reported0.00%period ending
RNAC Quarterly R&D/Revenue (480.85% → 0.00%)
Latest values, visible window
High-resolution chart · PNG
RNAC r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 0% | |
| 24,952.5641% | |
| 1,551.1088% | |
| 3,053.5398% | |
| 4,989.5973% | |
| 1,334% | |
| -1,489.5916% | |
| 2,945.7364% | |
| 37.8562% | |
| 166.7466% | |
| 271.3646% | |
| 198.4735% | |
| 338.7693% | |
| 313.641% | |
| 112.9324% | |
| 79.86% | |
| 48.8427% | |
| 52.028% | |
| 67.8692% | |
| 85.7698% | |
| 73.5544% | |
| 117.6833% | |
| 126.274% | |
| 300.4735% | |
| 0% | |
| 0% | |
| 227.7127% | |
| 0% | |
| 93,338.4615% | |
| 73,530% | |
| 1,135.7697% | |
| 0% | |
| 0% | |
| 0% | |
| 80,135.2941% | |
| 35,200% | |
| 42,284.6154% | |
| 8,061.3139% | |
| 376.5529% | |
| 574.5229% | |
| 297.4715% | |
| 318.3908% | |
| 337.91% | |
| 341.1948% | |
| 429.9353% | |
| 480.8511% |